The pathogenesis of osteoarthritis (OA) is not clearly understood; inflammatory mediators play an important role in the pathogenesis of OA. Non steroidal anti inflammatory drugs (NSAIDs) the most widely prescribed drugs in OA. The efficacy of two anti-inflammatory drugs proglumetacindimaleate (PRO) and diclofenac sodium (DIC) in controlling the pain response along with diseases was assessed. The study is a progressive study; patients were followed for 4 weeks period to assess the efficacy of the two different treatments.  It is an open labeled, randomized comparative study. The drugs used were PRO (300mg, bid) and DIC (50mg, bid) in osteoarthritis patients. Totally 60 patients of both sexes with moderate to severe osteoarthritis were included in this study. Clinical assessment was done based on the following parameters to assess the efficacy of the drugs and as well as the pain perception. X-ray was done to assess the joints and inflammation including swelling of the joints. The laboratory investigation includes routine haematogram, liver function tests, and kidney function test. The pain perception in the patients was measured using pain scale. The results have indicated that in comparison to PRO, DIC had toxicity in liver as observed by increased SGOT levels. The efficacy index for PRO and DIC was found to be 5.08±3.57 and 6.88±2.60 respectively.  The study can be concluded that both PRO and DIC exhibited similar efficacy and controlled the pain perception in OA patients. In any selection of drug of choice for the treatment and analyzing the risk versus benefit PRO has been preferred as NSAIDs due to its better tolerability in GIT complications as well as pro drug property. The precaution to be taken is periodical liver function tests on prolong use of PRO is required.

Keywords- Inflammation, COX inhibitors, Efficacy,Arthritis, analgesics.

1.      Dieppe P. Osteoarthritis and related disorders. Disorders of bone, cartilage and connective tissue. John H. Klippel, Paul A. Diepee. Rheumatology, Vol.2, 2^nd ed. 1998, London, P. 8/1.1 -8/1.2.

2.      Doherty M, Jones A, Cawston T.E. Osteoarthritis. Peter J.Mudison et al. Oxford Text book of Rheumatology. 2^nd ed. 1998, Oxford University press. New York. P. 151, 1540.

3.      Gibilisco PA, Schumacher HR, Jr, Hollander JL, Soper KA. Synovial fluid crystals in osteoarthritis. Arthritis Rheum. 1985;28:511–515.

doi: 10.1002/art.1780280507.

4.      Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B, Vignery A, et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. ProcNatlAcadSci U S A. 2011;108:14867–14872.

doi: 10.1073/pnas.1111101108.

5.      Scanzello CR, Plaas A, Crow MK. Innate immune system activation in osteoarthritis: is osteoarthritis a chronic wound? Curr Opin Rheumatol. 2008;20:565–572. doi: 10.1097/BOR.0b013e32830aba34.

6.      Sileghem. A, Verstreten. A, Dequeker J. Double blind randomized, parallel group study of the efficacy and safety of proglumetacin and naproxen in periarthritis of shoulder or elbow. Current Therapeutic Research 1991:50(1):93-94.

7.      Wang K, Xu J, Hunter DJ, Ding C. Investigational drugs for the treatment of osteoarthritis. Expert OpinInvestig Drugs. 2015;24(12):1539-56. doi:10.1517/13543784.2015.1091880. Epub 2015 Oct 1. Review. PubMed PMID: 26429673.

8.      Simon J.Brodsky. A, Famey. JJ. P, Randomized double blind study of the efficacy and tolerability of proglumetacin versus diclofenac in sports trauma. Current therapeutic Research 1993:53 (6):630.

9.      Boom TA, Franchimont P, Proglumetacin versus Indomethacin in Rheumatoid arthritis. A double blind multicentre study. Advances in Therapy 1994:11(5):228.